-
公开(公告)号：US20220017511A1
公开(公告)日：2022-01-20
申请号：US17183832
申请日：2021-02-24
申请人： AbbVie Inc.
发明人： Steven D. Fidanze , Lisa A. Hasvold , Dachun Liu , Keith F. McDaniel , John Pratt , Michael Schrimpf , George Sheppard , Le Wang , Bing Li
IPC分类号： C07D471/04
摘要： The present invention provides for compounds of formula (I) wherein R1, R2, R3, R4, R6, X1, and X2 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Also provided are pharmaceutical compositions comprising compounds of formula (I).
-
公开(公告)号：US20210047304A1
公开(公告)日：2021-02-18
申请号：US16883713
申请日：2020-05-26
申请人： AbbVie Inc.
发明人： Marlon Cowart , Steven Fidanze , Lisa Hasvold , Dachun Liu , Keith McDaniel , John Pratt , George Sheppard , Le Wang
IPC分类号： C07D405/12 , C07D401/12 , C07D401/14 , C07D403/04 , C07D403/14 , C07D487/10
摘要： The present invention provides for compounds of formula (I) wherein R1, Y, L1, G1, X1, X2, L2, R2, R3, and R4 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Also provided are pharmaceutical compositions comprising compounds of formula (I).
-
公开(公告)号：US09957263B2
公开(公告)日：2018-05-01
申请号：US14392201
申请日：2014-06-27
申请人： AbbVie Inc.
发明人： Yujia Dai , Steven D. Fidanze , Lisa Hasvold , James Holms , Dachun Liu , William McClellan , Keith McDaniel , Jasmina Marjanovic , George Sheppard , Le Wang
IPC分类号： C07D471/02 , A61K31/44 , A61K31/497 , C07D471/04 , A61K45/06 , A61K31/437 , A61K31/496 , A61K31/5377 , A61K31/541 , A61K31/551 , A61K31/4545 , A61K31/506
CPC分类号： C07D471/04 , A61K31/437 , A61K31/4545 , A61K31/496 , A61K31/497 , A61K31/506 , A61K31/5377 , A61K31/541 , A61K31/551 , A61K45/06
摘要： Compounds of formula (I) and pharmaceutically acceptable salts thereof are provided. The compounds are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Pharmaceutical compositions comprised of one or more compounds of formula (I) are also provided.
-
公开(公告)号：US09586978B2
公开(公告)日：2017-03-07
申请号：US14558318
申请日：2014-12-02
申请人： AbbVie Inc.
发明人： Mary E. Bellizzi , David A. Betebenner , Jean C. Califano , William A. Carroll , Daniel D. Caspi , David A. DeGoey , Pamela L. Donner , Charles A. Flentge , Yi Gao , Charles W. Hutchins , Douglas K. Hutchinson , Tammie K. Jinkerson , Warren M. Kati , Ryan G. Keddy , Allan C. Krueger , Wenke Li , Dachun Liu , Clarence J. Maring , Mark A. Matulenko , Christopher E. Motter , Lissa T. Nelson , Sachin V. Patel , John K. Pratt , John T. Randolph , Todd W. Rockway , Kathy Sarris , Michael D. Tufano , Seble H. Wagaw , Rolf Wagner , Kevin R. Woller
IPC分类号： A61K38/00 , C07K16/00 , C07F7/02 , C07D401/14 , C07D403/14 , C07D405/14 , C07D413/14 , C07D417/14 , C07D453/00 , C07D491/113
CPC分类号： A61K31/454 , A61K31/4178 , A61K31/4184 , A61K31/422 , A61K31/435 , A61K31/4355 , A61K31/438 , A61K31/4418 , A61K31/4439 , A61K31/4545 , A61K31/496 , A61K31/506 , A61K31/5377 , A61K31/695 , A61K45/06 , C07D401/14 , C07D403/14 , C07D405/14 , C07D413/14 , C07D417/14 , C07D453/00 , C07D491/113 , C07F7/02 , Y02P20/582
摘要： Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.
摘要翻译： 描述了有效抑制丙型肝炎病毒（“HCV”）复制的化合物。 本发明还涉及制备这种化合物的方法，包含这些化合物的组合物，以及使用这些化合物治疗HCV感染的方法。
-
公开(公告)号：US20160272630A1
公开(公告)日：2016-09-22
申请号：US14392201
申请日：2014-06-27
申请人： ABBVIE INC.
发明人： Yujia Dai , Steven D. Fidanze , Lisa Hasvold , James Holms , Dachun Liu , William McClellan , Keith McDaniel , Jasmina Marjanovic , George Sheppard , Le Wang
IPC分类号： C07D471/04 , A61K31/4545 , A61K31/5377 , A61K31/541 , A61K31/497 , A61K31/506 , A61K31/551 , A61K31/437 , A61K31/496
CPC分类号： C07D471/04 , A61K31/437 , A61K31/4545 , A61K31/496 , A61K31/497 , A61K31/506 , A61K31/5377 , A61K31/541 , A61K31/551 , A61K45/06
摘要： Compounds of formula (I) and pharmaceutically acceptable salts thereof are provided. The compounds are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Pharmaceutical compositions comprised of one or more compounds of formula (I) are also provided.
-
公开(公告)号：US09095590B2
公开(公告)日：2015-08-04
申请号：US14230965
申请日：2014-03-31
申请人： AbbVie Inc.
发明人： Rolf Wagner , Warren M. Kati , Dachun Liu , Yaya Liu , Kenton L. Longenecker , Clarence J. Maring , John K. Pratt , Todd W. Rockway , Kent D. Stewart , Michael D. Tufano
IPC分类号： C07D239/22 , C07D239/54 , A61K31/513 , C07D401/10 , C07D403/10 , C07D409/10 , C07D413/10 , C07D417/10 , A61K31/5377 , C07D405/10 , C07D417/14
CPC分类号： A61K31/513 , A61K31/5377 , C07D239/22 , C07D239/54 , C07D401/10 , C07D403/10 , C07D405/10 , C07D409/10 , C07D413/10 , C07D417/10 , C07D417/14
摘要： This invention relates to: (a) compounds and salts thereof that, inter alia, inhibit HCV; (b) intermediates useful for the preparation of such compounds and salts; (c) compositions comprising such compounds and salts; (d) methods for preparing such intermediates, compounds, salts, and compositions; (e) methods of use of such compounds, salts, and compositions; and (f) kits comprising such compounds, salts, and compositions.
-
公开(公告)号：US09050346B2
公开(公告)日：2015-06-09
申请号：US14203641
申请日：2014-03-11
申请人： AbbVie Inc.
发明人： Lisa A. Hasvold , Dachun Liu , Keith F. McDaniel , John Pratt , George S. Sheppard , Carol K Wada , Kevin R. Woller
IPC分类号： C07D401/02 , C07D401/10 , A61K31/437 , A61K31/4353 , A61K31/5377 , C07D471/04 , A61K31/496 , A61K31/497 , C07D487/04 , A61K31/501 , A61K31/519
CPC分类号： A61K31/5377 , A61K31/437 , A61K31/496 , A61K31/497 , A61K31/501 , A61K31/519 , C07D471/04 , C07D487/04 , Y02A50/463
摘要： The present invention provides for compounds of formula (I) wherein R1, R2, A1, A2, A3, A4, X, and Y have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Also provided are pharmaceutical compositions comprising one or more compounds of formula (I).
摘要翻译： 本发明提供式（I）化合物，其中R1，R2，A1，A2，A3，A4，X和Y具有说明书中定义的任何值及其药学上可接受的盐，其可用作 治疗疾病和病症，包括炎性疾病，癌症和艾滋病。 还提供了包含一种或多种式（I）化合物的药物组合物。
-
公开(公告)号：US20140315792A1
公开(公告)日：2014-10-23
申请号：US14180886
申请日：2014-02-14
申请人： AbbVie, Inc.
发明人： Rolf Wagner , John K. Pratt , Dachun Liu , Michael D. Tufano , David A. DeGoey , Warren M. Kati , Charles W. Hutchins , Pamela L. Dooner , John T. Randolph , Christopher E. Motter , Lissa T. Nelson , Sachin V. Patel , Mark A. Matulenko , Ryan G. Keddy , Tammie K. Jinkerson , Todd W. Rockway , Clarence J. Maring , Douglas K. Hutchinson , Charles A. Flentge , David A. Betebenner , Kathy Sarris , Kevin R. Woller , Seble H. Wagaw , Jean C. Califano , Wenke Li , Daniel D. Caspi , Mary E. Bellizzi , Yi Gao , Allan C. Krueger
IPC分类号： C07K5/06 , C07D417/14 , C07C33/26 , C07D403/14 , C07C205/19
CPC分类号： C07F9/65583 , C07C33/26 , C07C201/06 , C07C205/19 , C07D207/08 , C07D207/09 , C07D207/16 , C07D401/14 , C07D403/14 , C07D405/14 , C07D413/14 , C07D417/14 , C07D453/00 , C07D471/04 , C07D491/113 , C07K5/06
摘要： Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.
-
公开(公告)号：US20140080886A1
公开(公告)日：2014-03-20
申请号：US14029333
申请日：2013-09-17
申请人： AbbVie Inc.
发明人： Tami J. Pilot-Matias , Preethi Krishnan , Warren M. Kati , Christine A. Collins , Neeta C. Mistry , Clarence J. Maring , David A. DeGoey , John K. Pratt , Dachun Liu , Rolf Wagner
IPC分类号： A61K31/4025 , A61K45/06
CPC分类号： A61K31/4025 , A61K31/401 , A61K45/06 , A61K2300/00
摘要： Pan-genotypic HCV inhibitors are described. This invention also relates to methods of using these inhibitors to treat HCV infection.
-
公开(公告)号：US20210236508A1
公开(公告)日：2021-08-05
申请号：US16996090
申请日：2020-08-18
申请人： AbbVie Inc.
发明人： Le Wang , John K. Pratt , Keith F. McDaniel , Yujia Dai , Steven D. Fidanze , Lisa Hasvold , James H. Holms , Warren M. Kati , Dachun Liu , Robert A. Mantei , William J. McClellan , George S. Sheppard , Carol K. Wada
IPC分类号： A61K31/541 , C07D487/04 , C07D471/04 , A61K31/437 , A61K31/5025 , A61K31/5377 , A61K45/06
摘要： The present invention provides for compounds of formula (I) wherein A1, A2, A3, A4, X1, X2, Y1, L1, G1, Rx, and Ry have any of the values defined thereof in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Also provided are pharmaceutical compositions comprising one or more compounds of formula (I).
-
-
-
-
-
-
-
-
-
搜索结果
62 条记录 (耗时 0.071 秒)
